Brett P. Monia is the President and Chief Executive Officer of Ionis Pharmaceuticals Inc., a leading biotechnology company focused on developing RNA-targeted therapeutics. With a Ph.D. in Biochemistry from the University of Massachusetts, Dr. Monia has been with Ionis since 1989, contributing significantly to the company's growth and success. His early work at Ionis centered on the development of antisense oligonucleotide technology, which has been pivotal in advancing the field of RNA-targeted therapies. Throughout his career, Dr. Monia has been instrumental in advancing several of Ionis' key programs to clinical stages and eventual commercialization. He has co-authored over 150 scientific publications and holds numerous patents, reflecting his deep commitment to scientific innovation and drug development. Under his leadership as CEO, Ionis has expanded its pipeline and strengthened its position as a pioneer in the development of RNA-based medicines, with multiple drugs approved and many more in various stages of clinical trials. As President and CEO, Dr. Monia oversees the strategic direction of Ionis, guiding the company through the complex landscape of drug development and regulatory approval. His leadership is characterized by a focus on scientific excellence, patient-centric innovation, and strategic partnerships. Dr. Monia's vision for Ionis is to continue pushing the boundaries of RNA technology to address unmet medical needs, ultimately improving the lives of patients worldwide.